MEMANTINE HYDROCHLORIDE | A205825 | AMNEAL PHARMACEUTICALS OF NEW YORK LLC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Forest Laboratories Inc. et al v. Mylan Pharmaceuticals Inc. 7 patentsANDA 205825memantine hydrochloride | D. Del. | 2014-04-21 | Terminated 2015-11-20 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.4384
per ea
Lowest NADAC/Unit
$0.3152
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 65162078503MEMANTINE HCL ER 28 MG CAPSULE | $0.4384 | EA | Generic | — | 2026-06-17 |
| 65162078509MEMANTINE HCL ER 28 MG CAPSULE | $0.4384 | EA | Generic | — | 2026-06-17 |
| 65162078403MEMANTINE HCL ER 21 MG CAPSULE | $0.3287 | EA | Generic | — | 2026-06-17 |
| 65162078309MEMANTINE HCL ER 14 MG CAPSULE | $0.3213 | EA | Generic | — | 2026-06-17 |
| 65162078303MEMANTINE HCL ER 14 MG CAPSULE | $0.3213 | EA | Generic | — | 2026-06-17 |
| 65162078203MEMANTINE HCL ER 7 MG CAPSULE | $0.3152 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.